Updated:
Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biotech led by Robert Foster, developing rencofilstat for NASH and liver fibrosis.
Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for non-alcoholic steatohepatitis (NASH) and other fibrotic diseases. Led by CEO Dr. Robert Foster, the company's lead drug candidate, rencofilstat, is a cyclophilin inhibitor designed to reduce liver fibrosis. The company was formerly known as ContraVir Pharmaceuticals before rebranding, reflecting a strategic pivot toward hepatology. Hepion's strategy centers on advancing rencofilstat through clinical trials, with a focus on NASH, a condition with few FDA-approved treatments. The drug has been evaluated in Phase 2 trials, and the company has explored endpoints measuring liver function and fibrotic biomarkers. Its platform includes proprietary artificial intelligence-driven analytics to evaluate drug activity, though the core value driver remains clinical outcomes. The company is based in Edison, New Jersey, and trades on the Nasdaq under the ticker HEPA. As of mid-2024, Hepion has undertaken cost-cutting measures and explored strategic alternatives, including potential mergers or the sale of assets, reflecting the challenging funding environment for mid-stage biotech firms. Dr. Foster continues to serve as CEO and a board member. A distinguishing feature of Hepion is its embrace of AI for drug development analysis, attempting to map rencofilstat's complex mechanisms of action. However, the firm's structural reality is that of a small, publicly traded biotech navigating cash-constrained clinical development — a high-risk, high-reward posture common in the sector but distinct from the long-duration capital bases of family offices.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Principals
Robert Foster
Chief Executive Officer
Sector focus
Frequently asked questions
What is Hepion Pharmaceuticals' lead drug candidate?
Hepion's lead candidate is rencofilstat, a cyclophilin inhibitor being studied for non-alcoholic steatohepatitis (NASH) and other fibrotic liver diseases. It received Fast Track designation from the FDA for NASH. The drug aims to reduce liver fibrosis, a key driver of mortality in chronic liver disease patients.
What is Hepion's current financial position?
As a clinical-stage biotech, Hepion had limited cash reserves and announced a 1-for-20 reverse stock split in December 2024 to maintain its Nasdaq listing. The company has been exploring strategic alternatives including potential mergers, asset sales, or partnership deals to fund continued development.
How does Hepion's AI platform factor into its drug development?
Hepion has developed a proprietary AI-driven platform called AI-POWR to analyze rencofilstat's multi-faceted mechanisms of action. The system maps the drug's effects across different biological pathways and patient subpopulations, though the platform's commercial value remains secondary to the clinical trial outcomes of rencofilstat itself.
What clinical stage is rencofilstat in?
Rencofilstat has completed Phase 2 clinical trials for NASH. The company had been planning Phase 3 programs subject to securing additional funding or a strategic partner. As of late 2024, the clinical path forward remains contingent on the outcome of strategic review processes.
Who are Hepion's main competitors in the NASH space?
The NASH drug development landscape includes companies like Madrigal Pharmaceuticals, whose drug Rezdiffra received FDA approval in March 2024, as well as Intercept Pharmaceuticals and Inventiva. Hepion has historically positioned rencofilstat based on its different mechanism of action — cyclophilin inhibition rather than FXR agonism or THR-beta activation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: